Skip to content
LATEST
Health

Evotec and Bristol Myers win FDA clearance for second drug candidate

The cereblon E3 ligase modulator is scheduled to enter Phase 1 trials in 2027 under an oncology-focused molecular glue pact first signed in 2018.

Evotec and Bristol Myers win FDA clearance for second drug candidate

Evotec SE and Bristol Myers Squibb received clearance on Nov. 19 from the U.S. Food and Drug Administration for a second investigational drug candidate developed under their protein degradation alliance.

The cereblon E3 ligase modulator, known as a CELMoD, advances an eight-year-old discovery collaboration designed to target undruggable disease proteins, with clinical trials slated for 2027 following a first oncology candidate in March 2026.

"The progression of a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform," said Dr. Joanna Holbrook, chief scientific officer of Evotec, in a press release on Nov. 19. "We are systematically translating complex biology into development candidates. This achievement reinforces the value of our longstanding collaboration with Bristol Myers Squibb and further strengthens our confidence in the platform's potential to generate a growing pipeline of investigational drug candidates aimed at addressing substantial unmet medical needs."

Conventional small molecules rely on direct binding to disrupt receptor function, leaving roughly 90% of target proteins unreachable, according to Evotec. In contrast, molecular glues induce proximity between an E3 ubiquitin ligase and disease-relevant proteins to trigger their degradation, expanding potential interventions in oncology and other therapeutic fields.

The companies established their molecular glue partnership in 2018, when Evotec teamed with Celgene before its acquisition by Bristol Myers Squibb. The pact was broadened in 2022, pairing Evotec's PanOmics screening pipelines and PanHunter computational platform with Bristol Myers Squibb's specialized CELMoD library.

The initial molecule from the collaboration entered Phase 1 clinical development in March 2026 for patients with advanced clear cell renal cell carcinoma. The latest regulatory clearance follows an R&D leadership overhaul at Bristol Myers Squibb intended to bolster late-stage development in response to looming patent expirations, as Atlas360 reported in November.

Bristol Myers Squibb and Evotec plan to advance the newly cleared candidate into Phase 1 clinical trials in 2027.

Source: Press release, Evotec SE, Nov. 19, 2026.

More stories

Latest news